Rickenbach Josef Von Buys 23,190 Shares of Rein Therapeutics (NASDAQ:RNTX) Stock

Rein Therapeutics Inc. (NASDAQ:RNTX) Director Rickenbach Josef Von purchased 23,190 shares of the business’s stock in a transaction on Tuesday, May 26th. The stock was acquired at an average cost of $1.06 per share, with a total value of $24,581.40. Following the completion of the acquisition, the director directly owned 58,014 shares in the company, valued at $61,494.84. The trade was a 66.59% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Rein Therapeutics Stock Performance

Shares of NASDAQ RNTX opened at $1.11 on Friday. Rein Therapeutics Inc. has a twelve month low of $0.95 and a twelve month high of $2.18. The company has a market capitalization of $94.95 million, a price-to-earnings ratio of -0.58 and a beta of 1.42. The firm has a 50-day moving average of $1.32 and a two-hundred day moving average of $1.31.

Rein Therapeutics (NASDAQ:RNTX) last issued its quarterly earnings results on Friday, May 15th. The company reported ($0.19) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.30. As a group, research analysts predict that Rein Therapeutics Inc. will post -1.63 earnings per share for the current year.

Institutional Trading of Rein Therapeutics

A number of hedge funds have recently bought and sold shares of RNTX. Geode Capital Management LLC purchased a new stake in Rein Therapeutics during the second quarter valued at about $344,000. Northwestern Mutual Wealth Management Co. purchased a new stake in Rein Therapeutics during the second quarter valued at about $68,000. Cable Car Capital LP purchased a new stake in Rein Therapeutics during the second quarter valued at about $588,000. Gagnon Securities LLC lifted its stake in Rein Therapeutics by 218.8% during the third quarter. Gagnon Securities LLC now owns 228,692 shares of the company’s stock valued at $262,000 after buying an additional 156,947 shares in the last quarter. Finally, Vanguard Group Inc. lifted its stake in Rein Therapeutics by 32.2% during the third quarter. Vanguard Group Inc. now owns 1,168,407 shares of the company’s stock valued at $1,338,000 after buying an additional 284,300 shares in the last quarter. 90.89% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, Wall Street Zen raised shares of Rein Therapeutics to a “sell” rating in a report on Saturday, May 16th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $8.00.

Rein Therapeutics Company Profile

Rein Therapeutics is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies for patients with solid tumors. The company’s core technology is a tumor-activated interleukin-12 (IL-12) prodrug platform, designed to confine cytokine activity to the tumor microenvironment and thereby enhance anti-tumor immunity while minimizing systemic toxicity.

The lead candidate, RT-101, is currently in early-phase clinical trials targeting multiple solid tumor indications, including head and neck cancer and non-small cell lung cancer.